Experience of clinical use of atera a in patients with arterial hypertension associated with ischemic heart disease

Abstract

Introduction. The revolution in the treatment of arterial hypertension (AH) and coronary heart disease (IHD) is associated with the discovery of calcium antagonists (AC) and angiotensin II receptor agonists – sartans.Nowadays, treatment with these medicine has significant advantages. They are expressed in the fact that they are metabolically neutral, effective, have organoprotective properties, positively affect the end points of the course of AH. It is known that monotherapy is ineffective in high-risk patients, so it is advisable to use combined therapy, a combination of AK with sartans, in the treatment of patients with hypertension in combination with ischemic disease. Despite the great relevance of the problem, a small number of studies are devoted to this issue.Particularly popular among the combined medicine is the combination of telmisartan with amlodipine (known as “Ater A”).The purpose of the study. Study of clinical and hemodynamic effect of Ater A in patients with arterial hypertension associated with IHD in individuals with preserved LV systolic function.Materials and methods. The study covers 45 patients with arterial hypertention associated with IHD who were treated with the medicine Atera A. Clinical efficacy was assessed by lowering blood pressure (BP) to target levels and reducing the number of angina attacks. Hemodynamics indicators were studied by the method of echocardiography, Hypertrophy LV was stated in accordance with the recommendations of A.Canau et al. The myocardial mass of LV was calculated using the formula R.B. Devereux1995. Studies of the diastolic function of the heart were carried out by Doppler echocardiography. The studied indicators were determined before prescribing Atera A and after 10 weeks of taking the medicine.Reseach results. In the treatment of Atera A for 10 weeks both a decrease in systolic blood pressure (ATs) and diastolic blood pressure (ATd) was noted. The average daily ATs decreased by 35,9±2,20 mm Hg, or by 20,1±0,8% from the initial level (P<0,05), ATd – by 26,1±0,86 mm Hg, or by 18,1±0,8% (P<0,05). The heart rate (HR) did not increased.Conclusions. Medicine Atera A is characterized by high clinical efficacy and safety, which makes it the medicine of choice in the treatment of low-renin arterial hypertension in combination with coronary heart disease.